Haemonetics 1st Quarter Fiscal Year 2023 Earnings Release Available on Investor Relations Website

News provided by

Aug 10, 2022, 06:00 ET

Financial release accessible online

BOSTON, Aug. 10, 2022 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that financial results for its first quarter fiscal 2023, which ended July 2, 2022, are available on its Investor Relations website.

The Company will host a conference call and webcast with investors and analysts to discuss and answer questions about the results at 8:00 a.m. EDT on August 10, 2022. The conference call and webcast can be accessed with the following information:

Teleconference link: https://register.vevent.com/register/BI722ba0e696e749e6b514af4c2a3d3cc1
Once registration is completed, participants will receive a dial-in number along with a personalized PIN to access the call. While not required, it is recommended that participants join 10 minutes prior to the event start.
A live webcast of the call can be accessed on Haemonetics' investor relations website or via the following link: https://edge.media-server.com/mmc/p/dc896g7s

In addition, the Company has posted to its Investor Relations website the earnings release and analytical tables and supplemental information that will be referenced on its conference call and webcast, direct links to which are available below.

Direct link to 1Q FY23 Earnings Release:
https://haemonetics.gcs-web.com/static-files/28d85dc8-1d09-4355-937b-0cc17f6d51a5

Direct link to 1Q FY23 Analytical Tables and Supplemental Information:
https://haemonetics.gcs-web.com/static-files/4abb751e-3eb6-41a8-a06b-b3c48ba9d5c9

A replay of the conference call and webcast will be available for one year beginning on August 10, 2022, at 11:00 a.m. EDT using the conference call webcast link provided in this press release.

ABOUT HAEMONETICS
Haemonetics (NYSE: HAE) is a global healthcare company dedicated to providing a suite of innovative medical products and solutions for customers, to help them improve patient care and reduce the cost of healthcare. Our technology addresses important medical markets: blood and plasma component collection, the surgical suite and hospital transfusion services. To learn more about Haemonetics, visit www.haemonetics.com.

Investor Contacts:
Olga Guyette, Sr. Director-Investor Relations & Treasury	David Trenk, Manager-Investor Relations
(781) 356-9763	(203) 733-4987
[email protected]	[email protected]

Media Contact:
Josh Gitelson, Director-Global Communications
(781) 356-9776
[email protected]